Associated Papers
Impact of UGT1A4 Polymorphisms on the Posaconazole Serum Trough Concentrations in Patients With Acute Myeloid Leukemia Receiving Delayed-Release Tablets.
Parant F et al.
Therapeutic Drug Monitoring, 2025
UGT polymorphisms and epileptic seizure control in pregnant women treated with Lamotrigine.
Hansen NS et al.
Epilepsy Research, 2025
Controversies in our understanding of extreme hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient neonates.
Kaplan M et al.
Pediatric Research, 2025
Genome-wide analyses of neonatal jaundice reveal a marked departure from adult bilirubin metabolism.
Solé-Navais P et al.
Nature Communications, 2024
UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
Malhi V et al.
Cancer Chemotherapy and Pharmacology, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy.
Šušak Sporiš I et al.
Fundamental & Clinical Pharmacology, 2024
UGT1A4*3 polymorphism influences serum concentration and therapeutic effect of lamotrigine for epilepsy treatment: A meta-analysis.
Jiang Z et al.
Plos One, 2024
Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy.
Božina N et al.
European Journal of Clinical Pharmacology, 2023
Polymorphisms Affecting the Response to Novel Antiepileptic Drugs.
Urzì Brancati V et al.
International Journal of Molecular Sciences, 2023
Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients.
Petrenaite V et al.
Epilepsy Research, 2022
A validation study of the UGT1A4 rs2011404 variant and the risk of anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population.
Zhu J et al.
Journal of Clinical Pharmacy and Therapeutics, 2021
Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.
Wang ML et al.
Pharmacological Research, 2021
Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.
Božina N et al.
Arhiv Za Higijenu Rada I Toksikologiju, 2021
Metabolism of Long-Acting Rilpivirine After Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076).
Seneviratne HK et al.
Aids Research and Human Retroviruses, 2021
Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.
Soria-Chacartegui P et al.
Frontiers in Pharmacology, 2021
Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy.
Ortega-Vázquez A et al.
The Pharmacogenomics Journal, 2020
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.
Bojanic K et al.
International Journal of Environmental Research and Public Health, 2020
Genome-wide analyses disclose the distinctive HLA architecture and the pharmacogenetic landscape of the Somali population.
Ali AA et al.
Scientific Reports, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Meta-analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration.
Kim SC et al.
Basic & Clinical Pharmacology & Toxicology, 2019
Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy.
Wang ZZ et al.
Frontiers in Pharmacology, 2019
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Klarica Domjanović I et al.
British Journal of Clinical Pharmacology, 2018
Pharmacogenetics of ugt genes in North African populations.
Gaibar M et al.
The Pharmacogenomics Journal, 2018
Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects.
Gong J et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
UGT polymorphisms and lamotrigine clearance during pregnancy.
Petrenaite V et al.
Epilepsy Research, 2018
Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y et al.
European Journal of Clinical Pharmacology, 2017
No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients.
Shirzadi M et al.
Seizure, 2017
Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol.
Gonzalez-Covarrubias V et al.
Frontiers in Pharmacology, 2017
Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children.
Du Z et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2016
The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors.
Hoffmann MJ et al.
Bladder Cancer (amsterdam, Netherlands), 2016
Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Sutiman N et al.
Clinical Pharmacokinetics, 2016
Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.
Milosheska D et al.
British Journal of Clinical Pharmacology, 2016
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
Del Re M et al.
Pharmacological Research, 2016
Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine.
Reimers A et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2016
The Polymorphic Variant P24T of UDP-Glucuronosyltransferase 1A4 and Its Unusual Consequences.
Troberg J et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2015
Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?
Provenzani A et al.
International Journal of Clinical Pharmacy, 2015
Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy.
Wang Q et al.
Drug Metabolism and Pharmacokinetics, 2015
Pharmacogenetics of nicotine and associated smoking behaviors.
Tanner JA et al.
Current Topics in Behavioral Neurosciences, 2015
Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
Romero-Lorca A et al.
Plos One, 2015
Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China.
Chang Y et al.
European Journal of Clinical Pharmacology, 2014
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO et al.
Breast Cancer Research and Treatment, 2014
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO et al.
Breast Cancer Research and Treatment, 2013
Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients.
Singkham N et al.
European Journal of Clinical Pharmacology, 2013
Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations.
López M et al.
Molecular Biology Reports, 2013
Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.
Edavana VK et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2013
Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.
Erickson-Ridout KK et al.
Pharmacogenetics and Genomics, 2012
UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population.
Hakooz N et al.
Molecular Biology Reports, 2012
Pharmacogenomics of third-generation aromatase inhibitors.
Turkistani A et al.
Expert Opinion on Pharmacotherapy, 2012